Blog

如何实现药品研发中的动物实验向非动物实验的转型

Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…

Certara2026 年 5 月 5 日

Blog

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…

Certara2026 年 4 月 28 日

Blog

Top 10 Benefits of Simcyp® Simulator for Drug Development

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= 2026 年 4 月 23 日 Physiologically based pharmacokinetic (PBPK) modeling has evolved from an emerging methodology…

Certara2026 年 4 月 23 日

On-Demand Webinar

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Watch this on-demand webinar to learn how the final ICH M15 guidance is shaping Model-Informed…

Certara2026 年 4 月 2 日

On-Demand Webinar

充分发挥 PBPK 模型的全部潜力以加速药物研发

Explore how Novartis applies PBPK modeling in drug development using Simcyp to support regulatory decisions,…

Certara2026 年 3 月 20 日

博客

What are Common Bioequivalence Study Mistakes?

Learn about the most common bioequivalence study mistakes drug developers make and the differences between…

Certara2026 年 3 月 20 日

Blog

ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug Development

With the release of the draft ICH M15 guidance, MIDD is no longer optional -…

Certara2026 年 3 月 18 日

Conference

Discovery & Development Europe 2026

Certara2026 年 3 月 13 日

Announcement

Certara Expands Simcyp® Simulator to Streamline Regulatory Submissions and Internal Efficiencies

Discover how the Simcyp Simulator’s PBPK models can streamlines drug development and reduces the number…

Certara2026 年 3 月 5 日

博客

什么是 Simcyp Discovery 及其如何支持药物发现？

Learn how Simcyp helps in drug discovery, supporting compound selection, first-in-human PK prediction, early DDI…

Certara2026 年 3 月 3 日

Certara Products – Simcyp

如何实现药品研发中的动物实验向非动物实验的转型

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

Top 10 Benefits of Simcyp® Simulator for Drug Development

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

充分发挥 PBPK 模型的全部潜力以加速药物研发

What are Common Bioequivalence Study Mistakes?

ICH M15 Guideline: What the Finalized Guideline Means for Model-Informed Drug Development

Discovery & Development Europe 2026

Certara Expands Simcyp® Simulator to Streamline Regulatory Submissions and Internal Efficiencies

什么是 Simcyp Discovery 及其如何支持药物发现？

订阅时事通讯

快捷链接

解决方案

联系我们